The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid evolving dynamics in the U.S. healthcare sector, Bernstein SocGen Group has raised its price target for Cigna Group (CI) to $381 from $371 while maintaining an Outperform rating. The firm anticipates that Cigna will report a Q2 adjusted EPS of $7.56, driven by an improved medical loss ratio within its healthcare division. This revision is underpinned by a robust long-term outlook, with analysts projecting a 9.5% compound annual growth rate for earnings per share through 2030, suggesting the stock remains undervalued at current levels.
This bullish stance comes as sector peers navigate mixed headwinds; per market data, UnitedHealth Group (UNH) continues to face scrutiny over care costs, while recent earnings reports from Humana highlighted margin pressures due to elevated medical utilization rates (per Reuters). In contrast, Bernstein analysts suggest Cigna’s diversified model, particularly its Evernorth pharmacy benefits segment, provides a competitive edge and more predictable cash flows compared to pure-play insurers currently struggling with rising utilization.
From a market perspective, CI shares stood at $289.73 at the close of July 8, 2026, representing a significant discount to the new analyst target. Traders are monitoring support levels near the recent daily low of $284.23 for potential entry points. Looking ahead, the market will be watching the ISM Non-Manufacturing Prices data scheduled for release today, July 6, which could provide critical insights into service-sector inflation and its potential impact on healthcare operating costs.